Respiratory, Infectious Disease and Vaccines
The Respiratory, Infectious Disease and Vaccines Clinical Trials Team conducts clinical trials of new drugs for patients with respiratory conditions such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD), as well as respiratory infectious disease and lung cancer. The team also run clinical trials of new vaccines in healthy volunteers.
SNDX-6352-0506 - Axatilimab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Axatilimab is a “monoclonal antibody”, which is an antibody manufactured in a laboratory. It is designed to specifically block a protein believed to be involved in lung fibrosis. By blocking this protein, Axatilimab may slow or stop the progression of IPF.
Whistle-PF a new oral treatment for patients with Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF) or non-IPF Progressive Pulmonary Fibrosis (PPF)